预测中重度特应性皮炎患者减少 tralokinumab 给药频率的成功因素
该研究利用 ECZTRA 1 和 2 试验第 16 周应答者数据,采用机器学习分析切换 tralokinumab 至每 4 周一次后维持疗效的预测因素。结果显示第 16 周 IGA 0/1 和瘙痒 NRS < 3 是最强预测因子,稳定应答者切换后维持率与继续每 2 周一次相似,复发后恢复每 2 周一次可重新获得应答。
要点
- 第 16 周同时达到 IGA 0/1 和瘙痒 NRS < 3 的患者切换至每 4 周一次后维持应答率与继续每 2 周一次相似。
- 切换至每 4 周一次后复发的患者中 94.6% 在恢复每 2 周一次后重新获得应答。
- tralokinumab 免疫原性低,抗药抗体阳性患者未见疗效丧失或不良事件增加。
核心结论
- 对于初始每 2 周一次 tralokinumab 治疗达到稳定疾病控制(连续 4 周 IGA 0/1 且瘙痒 NRS < 3)的患者,每 4 周一次是有效的给药方案。
- 切换至每 4 周一次后复发的患者,恢复每 2 周一次可重新获得治疗应答。
研究设计与样本
- 事后分析,采用机器学习方法,数据来自 III 期 ECZTRA 1 和 2 试验第 16 周应答者人群。
- 应答者定义为接受 tralokinumab 每 2 周一次单药治疗第 16 周达到 IGA 0/1 和/或 EASI 75 的患者。
主要发现
- 第 52 周维持应答的两大预测因素为第 16 周 IGA 评分(76.1%)和第 16 周最严重每日瘙痒 NRS < 3(56.5%)。
- 第 12-16 周连续达到 IGA 0/1 和瘙痒 NRS < 3 的患者,第 52 周维持 IGA 0/1 应答率在每 2 周一次组为 72.0%,每 4 周一次组为 72.2%。
- 每 4 周一次组复发患者中 94.6% 在恢复每 2 周一次后重新获得应答。
- tralokinumab 免疫原性潜力低,抗药抗体阳性患者未显示疗效丧失或不良事件发生率升高。
关键数值与推荐
- 第 16 周 IGA 0/1 是最强预测因素(重要性 76.1%),其次为第 16 周最严重每日瘙痒 NRS < 3(56.5%)。
- 稳定应答定义为第 12-16 周连续 4 周达到 IGA 0/1 且瘙痒 NRS < 3。
临床怎么用
- 对于初始每 2 周一次 tralokinumab 治疗第 16 周达到 IGA 0/1 且瘙痒 NRS < 3 并稳定维持 4 周的患者,可考虑切换至每 4 周一次。
- 切换至每 4 周一次后复发的患者应及时恢复每 2 周一次给药以重新获得疾病控制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Approved tralokinumab maintenance dosing regimens for treatment of moderate-to-severe atopic dermatitis (AD) include 300 mg every 2 weeks (Q2W) and every 4 weeks (Q4W). Clinicians may consider tralokinumab Q4W for patients whose skin has become clear or almost clear at week 16 with initial Q2W dosing. OBJECTIVES: To identify predictive factors associated with maintained response after switching to tralokinumab Q4W, evaluate recapture of treatment response after relapse on Q4W, and assess treatment-emergent immunogenicity with tralokinumab Q4W. METHODS: These post hoc analyses utilized machine learning to identify predictive factors for maintained treatment response at week 52 using data from the week 16 responder population of the phase III ECZTRA 1 and 2 trials, i.e. patients who met Investigator's Global Assessment of clear/almost clear skin (IGA 0/1) and/or ≥ 75% improvement in Eczema Area and Severity Index (EASI 75) at week 16 with tralokinumab Q2W monotherapy. Top-ranked factors were then assessed individually and together to identify factors associated with a similar maintained efficacy at week 52 between patients rerandomized to tralokinumab Q2W or Q4W monotherapy at week 16. Additionally, the probability of recapturing IGA 0/1 and/or EASI 75 response after relapse was assessed in patients on tralokinumab Q4W transferred to the open-label arm. RESULTS: The two top-ranked predictive factors for maintained response at week 52 were IGA score at week 16 (76.1%) and worst daily pruritus numeric rating scale (NRS) < 3 at week 16 (56.5%). Patients whose AD reached stable clinical response scores of both IGA 0/1 and worst daily pruritus NRS < 3 from weeks 12-16 with tralokinumab Q2W similarly maintained IGA 0/1 response at week 52 regardless of dosing regimen beyond week 16 (72.0% of patients on Q2W and 72.2% of those on Q4W). Of patients who relapsed on Q4W, 94.6% recaptured treatment response after returning to Q2W dosing. The immunogenicity potential of tralokinumab was low, and patients with positive antidrug antibodies did not show loss of efficacy or higher incidences of adverse events. CONCLUSIONS: These data suggest that Q4W is an effective dosing regimen for most patients who achieved stable disease control as shown by clear/almost clear skin and no itch to mild itch over 4 consecutive weeks on the initial regimen of tralokinumab Q2W. Atopic dermatitis (AD) is a chronic, itchy skin disease. Patients whose AD can’t be controlled with topical (applied to the skin) prescription treatments often need long-term oral or injectable treatments. Tralokinumab is a biologic medication (derived from living organisms) that is injected under the skin. It is approved for treating AD at two different dosages: a standard initial dose of 300 mg every 2 weeks (Q2W) and a reduced dosing frequency option, every 4 weeks (Q4W) for patients who have achieved clear or almost clear skin with Q2W dosing. In our study, we analysed factors associated with maintaining clear/almost clear skin after switching from tralokinumab Q2W to Q4W, using data from two clinical trials (ECZTRA 1 and 2) funded by LEO Pharma A/S. In these trials, patients initially received tralokinumab Q2W for 16 weeks. Those who responded well either continued with Q2W dosing for another 36 weeks or switched to less frequent Q4W dosing. The top factors associated with maintenance of clear/almost clear skin were achievement of both clear/almost clear skin and experiencing no-to-mild itch symptoms at week 16. Among patients who experienced stable disease control with Q2W dosing (clear/almost clear skin and no-to-mild itch over a 4-week period), a similarly high percentage maintained clear/almost clear skin after switching to Q4W dosing as those who continued on Q2W dosing. Importantly, patients who worsened after switching to Q4W were able to regain disease control by returning to Q2W dosing. Our findings can help identify patients who are most likely to successfully switch from tralokinumab Q2W to Q4W.
引用
- Weidinger S, Bewley A, Hong HC, et al. Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis. Br J Dermatol. 2025. PMID: 39657020. doi:10.1093/bjd/ljae439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。